Paras Biopharmaceuticals
Innovations that Decode and Create Biologics Medicines for Unmet Medical Needs

Over the last few decades, we have witnessed a radical evolution of medicines for many rare ailments that were once deemed untreatable—all thanks to the technological advancement and sophistication that empowered pharmaceutical companies and bolstered their manufacturing environments to deliver unprecedented results. However, truth be told, we have just begun scratching the surface.

Even today, the complex and archaic workflows often hinder pharmaceutical organisations from meeting the patients’ unmet clinical needs. Although biologic therapies are playing a key role in handling such critical diseases, the lack of innovation in the manufacturing and production processes has been a major setback in most cases. Dr Ashesh Kumar, CEO and Director: Biologics & Licensing at Paras Biopharmaceuticals and a doctorate in the field of Biosciences & Biotechnology, says, “Extreme levels of inefficiencies in the manufacturing of biologics are responsible for increased costs and ineffective results in treating unmet clinical needs of patients.” To mitigate the inconsistency, the Paras Biopharmaceuticals team dived deep into the problem and figured that the challenge lies within the need for developing biologically active products via high productivity. The absence of a proper “biologic” structure results in a considerable loss in the number of useful protein parts and makes the drugs inefficacious.

Fundamentally, Paras Biopharmaceuticals’ primary objective and vision is to provide an economic solution for expensive medicine as part of its internal pipeline, together with its already successfully established end-to-end biologics CDMO production work that it offers to clients to assist their production work.

Setting this caveat as the founding principle of the company, the Paras Biopharmaceuticals team embarked on a journey with the sole objective of solving the inherent challenges of biologics manufacturing by incorporating out-of-the-box technologies. As an up-and-coming biopharmaceutical technology development company, Paras Biopharmaceuticals creates solutions that enable value creation and provide unmatched advantages in meeting unmet medical needs. “We have developed a technology platform (comprising offour technologies: Diabrid®, NobleCleav®, Biomultifold® and CytofoldStructQuant®) aimed primarily at removing the roadblocks while producing biologic medicines,” remarks Dr Mark Jackson.

Unlike its counterparts, one of the key features of Paras Biopharmaceuticals stems from its ability to produce active biologic proteins through its unique technology, namely CytofoldStructQuant®.

We have developed a platform based upon four sets of technologies aimed primarily at removing the roadblocks while producing biologic medicines for unmet medical needs in rare and orphan diseases

A proprietary technology of the company, CytofoldStructQuant®, enables the company to produce biologics within the living cells actively by fully folding the protein structures that keep the disulfide bonds intact. This way, it brings down costs of manufacturing and provides an affordable solution to patients.

In addition, Paras Biopharmaceuticals offers a wide spectrum of biopharmaceutical technologies for therapeutic peptides, proteins, and process technologies. The company’s stellar solution, Diabrid® Technology, allows it to offer one of the most economical ways to improve the production of expensive biopharmaceuticals. Paras Biopharmaceuticals has successfully incorporated a unique strategy to produce biologics, including therapeutic proteins and therapeutic peptides within Diabrid®, in a way that overcomes the many limitations of other available production approaches.

NobleCleav®, yet another outstanding solution from the Finland-based firm, promotes high-level production of authentic biologics by combining high specificity and activity of processing that reduces wastage. This, in turn, increases yields and significantly brings down the cost of production of biologics. Rounding off its technology suite is BioMultifold® Technology that provides an innovative and efficient process for the production of recombinant proteins using an E. Coli expression system. Making it possible to achieve expression levels of multigrams of therapeutic proteins per litre of fermentation, BioMultifold® is immensely useful for the large-scale production of novel biologics/biosimilars and therapeutic products at the commercial scale.

“We have a concept of developing flawless biologics; precisely the reason why along with our development team we work towards making clients’ processes as robust as possible from the very beginning,” affirms Dr Kumar. In fact, at the behest of its unprecedented offerings, Paras Biopharmaceuticals was able to yield positive outcomes for several of its customers, including a reputed European company and another US-based medium-sized firm. Being the exclusive developer and supplier for both, Paras Biopharmaceuticals successfully produced active biologics in bulk and enabled them to produce never-seen-before solutions through robust manufacturing processes.

With a strong technology front, Paras Biopharmaceuticals is smoothly scaling up its productivity levels and steering itself ahead of the competition curve. Besides, the company is even striving hard to cure unmet medical needs of complex ailments such as respiratory diseases, osteoarthritis, platelet disorders, and the likes of it. Presently working on some of the key challenges in the biopharmaceutical landscape, Paras Biopharmaceuticals is delighted to see its technology creating a spurn among organisations of all sizes. “This is opening new doors for us in terms of generating revenue and bringing critical projects,” states Dr Kumar. “We look forward to continuing contributing, enabling, and solving challenges upfront for unmet medical needs in the next 18 months and beyond.”